The evolution of phase I trials in cancer medicine: a critical review of the last decade

Por Tolcher, Anthony W.
Publicado em 2011

Innovative Therapies for Prostate Cancer Treatment

Por Syed, Samira, Tolcher, Anthony
Publicado em 2003

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Por de Bono, Johann S, Tolcher, Anthony W, Rowinsky, Eric K
Publicado em 2003

Changes of lung tumour volume on CT - prediction of the reliability of assessments

Por Beaumont, Hubert, Souchet, Simon, Labatte, Jean Marc, Iannessi, Antoine, Tolcher, Anthony William
Publicado no Cancer Imaging (2015)

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

Por Tolcher, Anthony W., Appleman, Leonard J., Shapiro, Geoffrey I., Mita, Alain C., Cihon, Frank, Mazzu, Arthur, Sundaresan, Pavur R.
Publicado em 2010

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

Por Vonderheide, Robert H., Burg, Jennifer M., Mick, Rosemarie, Trosko, Jennifer A., Li, Dongguang, Shaik, M. Naveed, Tolcher, Anthony W., Hamid, Omid
Publicado em 2013

Case report and summary of literature: giant perineal keloids treated with post-excisional radiotherapy

Por Jones, Kristin, Fuller, Clifton D, Luh, Join Y, Childs, Craig C, Miller, Alexander R, Tolcher, Anthony W, Herman, Terence S, Thomas, Charles R
Publicado em 2006

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α(5)β(1) Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Por Ricart, Alejandro D., Tolcher, Anthony W., Liu, Glenn, Holen, Kyle, Schwartz, Garry, Albertini, Mark, Weiss, Geoffrey, Yazji, Salim, Ng, Chee, Wilding, George
Publicado em 2008

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

Por Zuckerman, Jonathan E., Gritli, Ismael, Tolcher, Anthony, Heidel, Jeremy D., Lim, Dean, Morgan, Robert, Chmielowski, Bartosz, Ribas, Antoni, Davis, Mark E., Yen, Yun
Publicado em 2014

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Por Davis, Mark E., Zuckerman, Jonathan E., Choi, Chung Hang J., Seligson, David, Tolcher, Anthony, Alabi, Christopher A., Yen, Yun, Heidel, Jeremy D., Ribas, Antoni
Publicado em 2010

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advance...

Por Li, Tianhong, LoRusso, Patricia, Maitland, Michael L., Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A., Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Publicado no J Hematol Oncol (2016)

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

Por Smith, David C., Chugh, Rashmi, Patnaik, Amita, Papadopoulos, Kyriakos P., Wang, Min, Kapoun, Ann M., Xu, Lu, Dupont, Jakob, Stagg, Robert J., Tolcher, Anthony
Publicado no Invest New Drugs (2018)

A Randomized Phase II Trial Comparing 3-hour Versus 96-hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Por Moulder, Stacy L., Holmes, Frankie A., Tolcher, Anthony W., Thall, Peter, Broglio, Kristine, Valero, Vicente, Buzdar, Aman U., Arbuck, Susan G., Seidman, Andrew, Hortobagyi, Gabriel N.
Publicado em 2010

Phase I Dose-Escalation Study of EZN-2208 (PEG-SN38), a Novel Conjugate of Poly(ethylene) Glycol and SN38, Administered Weekly in Patients With Advanced Cancer

Por Patnaik, Amita, Papadopoulos, Kyriakos P., Tolcher, Anthony W., Beeram, Muralidhar, Urien, Saïk, Schaaf, Larry J., Tahiri, Sanaa, Bekaii-Saab, Tanios, Lokiec, François M., Rezaï, Keyvan, Buchbinder, Aby
Publicado em 2013

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Por Tolcher, Anthony W., Mita, Alain, Lewis, Lionel D., Garrett, Christopher R., Till, Elizabeth, Daud, Adil I., Patnaik, Amita, Papadopoulos, Kyri, Takimoto, Chris, Bartels, Pamela, Keating, Anne, Antonia, Scott
Publicado no J Clin Oncol (2008)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

Por Munasinghe, Wijith, Stodtmann, Sven, Tolcher, Anthony, Calvo, Emiliano, Gordon, Michael, Jalving, Mathilde, de Vos-Geelen, Judith, Medina, Diane, Bergau, Dennis, Nuthalapati, Silpa, Hoffman, David, Shepherd, Stacie, Xiong, Hao
Publicado no Cancer Chemother Pharmacol (2016)

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer

Por Gunn, Shelly, Reveles, Xavier, Weldon, Korrie, Barrera, Andres, Ishaque, Mariam, Taylor, Dale, McCaskill, Chris, Kim, Jaeweon, Shah, Rashmi, Mohammed, Mansoor, Barry, Todd, Kaiser, Brianne, Patnaik, Amita, Tolcher, Anthony
Publicado em 2013

A Phase 1 Study of Anti-TGFβ Receptor Type-II Monoclonal Antibody LY3022859 in Patients with Advanced Solid Tumors

Por Tolcher, Anthony W., Berlin, Jordan D., Cosaert, Jan, Kauh, John, Chan, Emily, Piha-Paul, Sarina A., Amaya, Alex, Tang, Shande, Driscoll, Kyla, Kimbung, Richard, Prasad Kambhampati, S. R., Gueorguieva, Ivelina, Hong, David S.
Publicado no Cancer Chemother Pharmacol (2017)

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

Por Goldman, Jonathan W., Rosen, Lee S., Tolcher, Anthony W., Papadopoulos, Kyriakos, Beeram, Muralidhar, Shi, Peipei, Pitou, Celine, Bell, Robert, Kulanthaivel, Palaniappan, Zhang, Xuekui, Fink, Aaron, Chan, Edward M., Shahir, Ashwin, Farrington, Daphne, Patnaik, Amita
Publicado no Invest New Drugs (2017)

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

Por Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Publicado em 2013